Please upgrade your browser.
Abstracts in Renal Cell Carcinoma and Trials in Progress Abstracts will be accepted for poster display at the 10th International Kidney Cancer Symposium, October 14-15, in Chicago.
An increasing number of cancer patients are using complementary and alternative medicine (CAM) without their physicians' knowledge, putting them at risk of adverse interactions with conventional medicine, according to a review published today.
According to a latest study, for patients suffering from kidney cancer, it is always better to get the damaged part of kidney removed rather than getting the entire organ, because in later cases, the patients are then more likely to have renal complications and poorer health after surgical treatment.
We present three cases of pancreatic metastases from clear renal carcinoma confirmed with 64-row MSCT and with histological confirmation of primary RCC and related metastases.
A number of new agents have been approved for systemic therapy of metastatic renal cell carcinoma (mRCC) recently. Thereby, prognostic factors may aid in predicting the effectiveness of various treatment modalities in individual cases. Aim of this study was to determine the value of human leukocyte antigen (HLA) class II characteristics in predicting response of mRCC to combined immunochemotherapy (ICT).
U.S. Patent and Trademark Office has issued patent number 7,901,879, entitled, "Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases."
The drug would also be the first in a new class of immune- boosting medicines able to treat an array of tumors. Anti-PD-1, shrunk or stabilized tumors in 8 of 16 kidney cancer patients, researchers reported at a medical conference earlier this year.
The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging. NCCN convened a multidisciplinary task force panel to address the clinical issues associated with these therapies in attempt to help practicing oncologists optimize patient outcomes.
|NeonCRM by Neon One|